Abstract

Naturally derived diosmetin and its glycoside diosmin are known to be effective in treating inflammatory disease. The aim of this study was to investigate the anti‐atopic dermatitis effect on diosmetin and diosmin 2,4‐dinitrochlorobenzen (DNCB)‐induced atopic dermatitis (AD) models. Oral administration of diometin or diosmin inhibited the development of DNCB‐induced AD‐like lesions in hairless mice by inhibiting transdermal moisture loss (TEWL) and improving skin hydration. Total serum immunoglobulin E (IgE) and interleukin‐4 (IL‐4) levels were also reduced in AD‐like lesion hairless mice skin samples treated with diosmetin or diosmin. In vitro, however, only diosmetin reduced the level of IL‐4 mRNA in RBL‐2H3 cells. Diosmin considered to be effective in the treatment of AD and skin inflammatory diseases by being converted into diosmetin in the body by pharmacokinetic metabolism. Thus oral administration of diosmetin and diosmin might be useful for the treatment of AD and cutaneous inflammatory diseases.Support or Funding InformationThis research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF)& funded by the Korean government (MSIT) (Nos. NRF‐2019M3A9I3080263, NRF‐2019M3A9I3080265, and NRF‐2019M3A9I3080266).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.